Esperion Therapeutics: 15 Reasons to Take Profits

On Wednesday, the folks at Barclays initiated Esperion Therapeutics (ESPR) at Outperform (along with Alkermes (ALKS) and Intercept Pharmaceuticals (ICPT)). Today Chardan Capital Markets analyst Gbola Amusa started Esperion as a Sell–and offered 15 reason “take profits” now. Here they are: Reason 1: Pfizer (PFE) opted to not develop ETC-1002. Pfizer effectively sold ETC-1002 [a cholesterol-fighting drug] [...]